Human Papilloma Virus (HPV) High Risk, Nucleic Acid Testing
Human Papillomavirus or HPV is the most common non-reportable sexually transmitted infection in the United States (C. trachomatis and N. gonorrhoeae are the #1 and #2 most common reportable infections, respectively). Approximately 20 million Americans, or ~15% of the population, are currently infected, with approximately 6.2 million new infections each year. Infections are common in both men and women, especially between 15 - 49 years of age. Statistically, more than 75% of sexually active women have been exposed to HPV by age 18 - 22.
HPV is a member of the papilloma virus family, which contains greater than 200 different HPV types. Over half of all sexually active adults are thought to have been infected with at least one strain of HPV in their lifetime. HPV causes a wide range of infections, including common and genital warts, and genital and anal cancers. HPV normally causes a transient, benign infection. It is medically significant, however, due to its strong association with cervical cancer, with >99% of cervical cancers associated with HPV infection. Worldwide, close to half a million women are diagnosed with cervical cancer each year and close to 300,000 die from the disease. In the US, the CDC estimates that there are close to 11,000 new cervical cancers diagnosed each year and 3,900 women will die. While HPV is the major cause of cervical cancer, not everyone who is infected with HPV will develop the disease. Ninety-five percent of HPV-positive individuals will spontaneously clear the disease without further problems.
The types of HPV that infect the genital tract are divided into two risk categories based on their association with causing cervical cancers. Types that are rarely associated with cancers, but cause other genital infections, are classified as low-risk types. These include types 6 and 11, which cause genital warts or condylomas. High-risk types are those that have been shown to have a strong association with cervical cancers. These include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 82.
Implementation of a universal HPV screening program in 2002 has helped to greatly reduce the incidence of cervical cancer. The guidelines recommend screening women over the age of 30 for HPV in conjunction with a PAP smear. If the patient is negative for HPV, and has a normal PAP smear, screening is recommended at 2 - 3 year intervals. If the patient is positive for HPV, and has an abnormal PAP, they may be sent for additional or follow-up testing. Diagnosing infection requires detection of HPV using molecular techniques. It does not easily grow in culture. Identification requires a cellular sample from the site of infection, which is usually collected as a single sample in conjunction with the PAP smear.
- Diagnostic screening for cervical cancer
- HPV testing for the triage of patients showing atypical squamous cells of undetermined significance (ASC-US)
- HPV testing associated with high-grade squamous intraepithelial lesions (HSIL)
- HPV testing associated with low grade squamous intraepithelial lesions (LSIL)
- Repeat HPV testing in patients with previous positive testing for HPV and negative cytology
- Follow-up testing after the treatment
Positive in:
- Patients infected with HPV
- Patients with ASCUS and abnormal PAP smear, some.
- Patients with CIN-1, CIN-2, and CIN-3, most.
Negative (Not detected)
Cells from the cervix or endocervix are collected using a brush or spatula in liquid cytology media ThinPrep or SurePath.
Specimens can be also collected using swab and transport in viral transport media or any molecular media. Biopsy can be also used, however, cells must be separate using protease for detection by flow cytometry.
Stability
- ThinPrep and SurePath specimens are stable up to 21 days
- Viral transport media are stable up to 7 days
- J Clin Microbiol. 2011 Dec;49(12):4185-9. [PMID: 21998422]
- J Natl Compr Canc Netw. 2008 Jan;6(1):83-95. PMID: 18267061]
- Gynecol Oncol. 2006 Oct;103(1):12-7. Epub 2006 Aug 24. [PMID: 16934860]
- J Clin Virol. 2005 Mar;32 Suppl 1:S43-51. [PMID: 15753011]
- J Clin Microbiol. 2006 Nov;44(11):3915-7. Epub 2006 Sep 13. [PMID: 16971652]
- J Clin Microbiol. 2008 Apr;46(4):1161-8. Epub 2008 Jan 30. [PMID: 18234872]